Asunto(s)
Antígenos Bacterianos/sangre , Proteínas de la Membrana Bacteriana Externa/análisis , Bordetella pertussis/aislamiento & purificación , Vacuna contra la Tos Ferina/inmunología , Factores de Virulencia de Bordetella/análisis , Tos Ferina/epidemiología , Adolescente , Adulto , Anciano , Bordetella pertussis/inmunología , Niño , Preescolar , Ensayo de Inmunoadsorción Enzimática , Proteínas Fimbrias/sangre , Hemaglutininas/sangre , Humanos , Lactante , Persona de Mediana Edad , Toxina del Pertussis/sangre , Vacuna contra la Tos Ferina/uso terapéutico , Prevalencia , Estudios Retrospectivos , Eslovenia/epidemiología , Adulto JovenRESUMEN
Despite more than 50 years of vaccination, pertussis is still an endemic disease, with regular epidemic outbreaks. With the exception of Poland, European countries have replaced whole-cell vaccines (WCVs) by acellular vaccines (ACVs) in the 1990s. Worldwide, antigenic divergence in vaccine antigens has been found between vaccine strains and circulating strains. In this work, 466 Bordetella pertussis isolates collected in the period 1998-2012 from 13 European countries were characterised by multi-locus antigen sequence typing (MAST) of the pertussis toxin promoter (ptxP) and of the genes coding for proteins used in the ACVs: pertussis toxin (Ptx), pertactin (Prn), type 2 fimbriae (Fim2) and type 3 fimbriae (Fim3). Isolates were further characterised by fimbrial serotyping, multi-locus variable-number tandem repeat analysis (MLVA) and pulsed-field gel electrophoresis (PFGE). The results showed a very similar B. pertussis population for 12 countries using ACVs, while Poland, which uses a WCV, was quite distinct, suggesting that ACVs and WCVs select for different B. pertussis populations. This study forms a baseline for future studies on the effect of vaccination programmes on B. pertussis populations.
Asunto(s)
Bordetella pertussis/clasificación , Bordetella pertussis/aislamiento & purificación , Variación Genética , Tos Ferina/epidemiología , Tos Ferina/microbiología , Antígenos Bacterianos/genética , Bordetella pertussis/genética , Electroforesis en Gel de Campo Pulsado , Europa (Continente)/epidemiología , Humanos , Repeticiones de Minisatélite , Epidemiología Molecular , Tipificación de Secuencias Multilocus , Toxina del Pertussis/genética , Regiones Promotoras Genéticas , SerotipificaciónRESUMEN
Pathogen adaptation has been proposed to contribute to the resurgence of pertussis. A striking recent example is the emergence of isolates deficient in the vaccine component pertactin (Prn). This study explores the emergence of such Prn-deficient isolates in six European countries. During 2007 to 2009, 0/83 isolates from the Netherlands, 0/18 from the United Kingdom, 0/17 Finland, 0/23 Denmark, 4/99 Sweden and 5/20 from Norway of the isolates collected were Prn-deficient. In the Netherlands and Sweden, respectively 4/146 and 1/8 were observed in a later period (201012). The Prn-deficient isolates were genetically diverse and different mutations were found to inactivate the prn gene. These are indications that Prn-deficiency is subject to positive selective pressure. We hypothesise that the switch from whole cell to acellular pertussis vaccines has affected the balance between 'costs and benefits' of Prn production by Bordetella pertussis to the extent that isolates that do not produce Prn are able to expand. The absence of Prn-deficient isolates in some countries may point to ways to prevent or delay the spread of Prn-deficient strains. In order to substantiate this hypothesis, trends in the European B. pertussis population should be monitored continuously.
Asunto(s)
Proteínas de la Membrana Bacteriana Externa/análisis , Proteínas de la Membrana Bacteriana Externa/genética , Bordetella pertussis/aislamiento & purificación , Factores de Virulencia de Bordetella/análisis , Factores de Virulencia de Bordetella/genética , Tos Ferina/prevención & control , Secuencia de Aminoácidos , Secuencia de Bases , Bordetella pertussis/genética , Niño , Preescolar , Análisis por Conglomerados , Enfermedades Transmisibles Emergentes/genética , ADN Bacteriano/genética , Europa (Continente) , Femenino , Genotipo , Humanos , Lactante , Masculino , Tipificación Molecular , Reacción en Cadena de la Polimerasa , Polimorfismo de Nucleótido Simple , Análisis de Secuencia de ADN , Tos Ferina/epidemiología , Tos Ferina/microbiologíaRESUMEN
Despite extensive childhood immunisation, pertussis remains one of the world's leading causes of vaccine preventable deaths. The current methods used for laboratory diagnosis of pertussis include bacterial culture, polymerase chain reaction (PCR) and enzyme linked immunosorbent assay (ELISA) serology. We conducted a questionnaire survey to identify variations in the laboratory methods and protocols used among participating countries included in the European surveillance network for vaccine-preventable diseases(EUVAC.NET). In February 2010, we performed the survey using a web-based questionnaire and sent it to the country experts of 25 European Union countries,and two European Economic Area (EEA) countries,Norway and Iceland. The questionnaire consisted of 37 questions which covered both general information on surveillance methods and detailed laboratory methods used. A descriptive analysis was performed.Questionnaires were answered by all 27 contacted countries. Nineteen countries had pertussis reference laboratories at the national level; their functions varied from performing diagnosis to providing technical advice for routine microbiology laboratories. Culture,PCR and serology were used in 17, 18 and 20 countries,respectively. For PCR, nine laboratories used insertion sequence IS481 as the target gene, which is present in multiple copies in the Bordetella pertussis genome and thus has a greater sensitivity over single copy targets, but has been proved not to be specific for B.pertussis. Antibodies directed against pertussis toxin(PT) are specific for B. pertussis infections. For ELISA serology, only 13 countries' laboratories used purified PT as coating antigen and 10 included World Health Organization (WHO) or Food and Drug Administration (FDA) reference sera in their tests. This present survey shows that methods used for laboratory confirmation of pertussis differ widely among European countries and that there is a great heterogeneity of the reference laboratories and functions. To evaluate the effects of different pertussis immunisation programmes in Europe, standardisation and harmonisation of the laboratory methods are needed.